News
Eli Lilly says new GLP-1 weight loss pill could reach market in 2026
Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill for FDA approval by the end of the year. The pill does not produce the same amount of weight loss as injections,
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...
As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly (NYSE:LLY) is set to report Q2 earnings on Thursday, August 7, before the market opens, with Wall Street closely ...
Eli Lilly's experimental GLP-1 pill showed a 12.4% body weight reduction, less than Novo Nordisk's injectable Wegovy in a ...
On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...
8hon MSN
Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback